Dermata Therapeutics (DRMA) Operating Income (2020 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Operating Income of -$1.9 million for Q1 2026, up 17.67% year-over-year from -$1.6 million in Q1 2025, and down 1.37% quarter-over-quarter from -$1.9 million in Q4 2025.
Dermata Therapeutics (DRMA) Operating Income (2020 - 2026) Analysis & Trends
Dermata Therapeutics' Operating Income history runs 7 years deep, the most recent figure standing at -$1.9 million for Q1 2026.
- In Q1 2026, Operating Income rose 17.67% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at -$7.4 million (up 36.82% YoY), while the FY2025 annual figure was -$7.8 million, up 37.88% from the prior year.
- Operating Income for Q1 2026 stood at -$1.9 million, down from -$1.9 million in the prior quarter.
- The five-year high for Operating Income was -$1.7 million in Q4 2022, with the low at -$3.2 million in Q3 2024.
- The 5-year median for Operating Income is -$2.3 million (2023), against an average of -$2.3 million.
- The sharpest annual moves came in 2022 and 2025: Operating Income plunged 105.31% in 2022, then surged 45.42% in 2025.
- Dermata Therapeutics' Operating Income stood at -$1.7 million in 2022, then decreased by 29.69% to -$2.2 million in 2023, then slumped by 44.17% to -$3.2 million in 2024, then surged by 40.62% to -$1.9 million in 2025, then declined by 1.37% to -$1.9 million in 2026.
- Business Quant data shows DRMA's Operating Income at -$1.9 million in Q1 2026, -$1.9 million in Q4 2025, and -$1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Dermata Therapeutics | 5.33 Mn | 5.33 Mn | - | -1.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.93 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Sep 30, 2025 | -1.76 Mn |
| Jun 30, 2025 | -1.77 Mn |
| Mar 31, 2025 | -2.34 Mn |
| Dec 31, 2024 | -3.20 Mn |
| Sep 30, 2024 | -3.23 Mn |
| Jun 30, 2024 | -2.88 Mn |
| Mar 31, 2024 | -3.20 Mn |
| Dec 31, 2023 | -2.22 Mn |
| Sep 30, 2023 | -1.81 Mn |
| Jun 30, 2023 | -1.73 Mn |
| Mar 31, 2023 | -2.28 Mn |
| Dec 31, 2022 | -1.71 Mn |
| Sep 30, 2022 | -2.45 Mn |
| Jun 30, 2022 | -2.73 Mn |
| Mar 31, 2022 | -2.79 Mn |
| Dec 31, 2021 | -2.55 Mn |
| Sep 30, 2021 | -1.71 Mn |
| Jun 30, 2021 | -1.33 Mn |